重新评估红醇 (E 968) 作为食品添加剂的使用
EFSA journal. European Food Safety Authority
|December 21, 2023
概括
红醇 (E 968) 是一种糖醇,可能导致腹和电解质失衡. 高摄入量超过可接受的每日摄入量 (ADI),带来风险. 没有支持豁免药警告标签.
科学领域:
- 食品科学 食品科学 食品科学
- 毒理学 毒理学 毒理学
- 公共卫生 公共卫生
背景情况:
- 红醇 (E 968) 是一种用作食品添加剂的聚醇,通过发酵产生.
- 它被人体吸收,并通过尿液排出不变,没有遗传毒性问题.
- 该研究重新评估了红醇的安全性,并申请豁免药警告标签.
研究的目的:
- 评估红醇 (E 968) 作为食品添加剂的安全性.
- 评估申请豁免脱剂警告标签要求的申请.
- 根据暴露水平来确定红醇消费带来的不良影响风险.
主要方法:
- 关于红醇的人类干预研究的综述.
- 确定对腹的没有观察到不良影响水平 (NOAEL).
- 计算可接受的每日摄入量 (ADI) 并与饮食暴露估计值进行比较.
主要成果:
- 红醇可以引起腹,由于潜在的电解质和水失衡,被认为是不利的.
- 确定了0.5g/kg体重 (bw) 的NOAEL,将每天的ADI设置为0.5g/kg bw.
- 估计的饮食暴露水平,特别是对于儿童和青少年来说,超过了ADI,表明潜在的风险.
结论:
- 现有数据不支持将红醇 (E 968) 免除药警告标签要求.
- 摄入大量的红醇可能会导致不良反应,包括腹和潜在的慢性问题.
- 摄入量较高的消费者可能会因单次和重复暴露而面临不良影响的风险.
相关概念视频
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...


